Schedule 13D - Activist Investments
SCHEDULE 13D/A: Thomas Meyer Boosts Stake in Altamira Therapeutics, Now Holding 18.9% of Common Shares
Thomas Meyer, a significant shareholder, increased his beneficial ownership in Altamira Therapeutics Ltd. to 18.9% after receiving 1,053,392 common shares as a bonus.
Schedule 13G - Passive Investments
Armistice Capital, LLC and its managing member Steven Boyd have disclosed a beneficial ownership of 9.99% in Altamira Therapeutics Ltd., holding 473,870 common shares.
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% in Altamira Therapeutics Ltd., holding 478,547 common shares as of December 31, 2024.